Core Insights - Broyhill Asset Management's fourth-quarter 2025 investor letter highlights extreme market concentration and a strong focus on artificial intelligence, resulting in many sectors being left behind [1] - The portfolio has been significantly reshaped and now trades at a substantial discount compared to the broader market, with the firm expecting to benefit as market fundamentals improve [1] - The portfolio declined by 1.4% for the year, underperforming the MSCI ACWI's 22.9% return, indicating a market dominated by momentum rather than fundamentals [1] Company Highlights - IQVIA Holdings Inc. (NYSE:IQV) is identified as one of the top contributors to Broyhill's portfolio, recognized for its role as a leading provider of clinical research services and healthcare intelligence [2][3] - As of February 25, 2026, IQVIA's stock closed at $161.91 per share, with a one-month return of -31.28% and a 52-week loss of 13.18%, while its market capitalization stands at $27.573 billion [2] - The company is noted for its durable business model and identifiable catalysts that the market has mispriced, contributing meaningfully as fears around biotech funding and clinical activity began to ease [3] Market Sentiment - Despite IQVIA's potential, it is not among the 30 most popular stocks among hedge funds, with 69 hedge fund portfolios holding the stock at the end of Q4, up from 61 in the previous quarter [4] - The sentiment towards the biotech sector remains fragile, but IQVIA's critical role in drug development is considered unchallenged, with expectations for a recovery in the industry [3] - The firm suggests that certain AI stocks may offer greater upside potential and less downside risk compared to IQVIA, indicating a competitive landscape for investment opportunities [4]

Group 1: Company Performance and Financials - IQVIA reported fourth-quarter revenue of $4.36 billion, exceeding the consensus estimate of $4.08 billion [3] - The company achieved near double-digit revenue and EPS growth in 2025, with strong performance across all segments [3] - CEO Ari Bousbib highlighted that expanded go-to-market efforts, operational discipline, and AI-related investments supported topline growth [3] Group 2: Analyst Ratings and Price Target - Morgan Stanley lowered its price target on IQVIA Holdings Inc. to $240 from $265 but maintained an Overweight rating [1][5] - The adjustment in price target followed the company's quarterly results [1] Group 3: Strategic Collaborations - IQVIA and the Duke Clinical Research Institute announced a collaboration to advance clinical research in obesity and related cardiometabolic trials [2] - The partnership aims to set a new standard for collaboration between life science service companies and academic research organizations, focusing on improving trial efficiency [2]